KCNH1 and carcinoma: In a clinical study, expression of Kv10.1 in brain metastases relative to matched primary carcinomas (various subtypes) was found to be highly variable—higher in 60%, unchanged in 26.7%, and lower in 13.3% of cases (n = 30) [62].